On October 21, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, BriaCell’s next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The collaboration starts with manufacturing, IND development and clinical protocol support for a Phase 1 clinical trial with Bria-BRES+, BriaCell’s next generation personalized immunotherapy for patients with breast cancer under the Bria-OTS+ platform. The partnership expands on BriaCell’s previously-announced selection into MSK’s accelerator program .
As one of the world’s foremost cancer research and treatment institutions, MSK has more than 135 years of leadership in patient care, education and discovery. Through the MSK Therapeutics Accelerator, MSK’s therapeutic-based strategic collaboration program, BriaCell will obtain access to MSK’s clinical and institutional expertise, including cell therapy manufacturing, Investigational New Drug (IND) preparation and submission and clinical development to expedite development of the Bria-OTS+ platform.
"We are thrilled to collaborate with MSK’s scientific and clinical experts to address the urgent unmet medical need of many thousands of metastatic breast cancer patients," stated Dr. William V. Williams, BriaCell’s President and CEO.
"We are honored to be working with the team of cancer specialists at MSK," noted Miguel Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. "This collaboration with MSK will accelerate the development of our advanced personalized off-the-shelf immunotherapy platform, Bria-OTS+, which we believe has the potential to transform cancer care and significantly improve patients’ lives through its unique mechanism of action."
"We look forward to working with BriaCell through MSK’s Therapeutics Accelerator to help advance this next-generation personalized immunotherapy into the clinic. Collaborations like this are essential to translating promising scientific innovations into potential new treatment options for patients," commented Shanu Modi, MD, Breast Medical Oncologist and Attending Physician at MSK.
(Press release, BriaCell Therapeutics, OCT 21, 2025, View Source [SID1234656937])